"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","growth_protocol_ch1","growth_protocol_ch1.1","growth_protocol_ch1.2","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","data_processing","data_processing.1","platform_id","contact_name","contact_email","contact_phone","contact_laboratory","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","cell type:ch1","gender:ch1","phase:ch1","tissue:ch1"
"GSM1174408","Control Endometrium Mesenchymal Cell_ETB65 ++","GSM1174408","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Mesenchymal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174408/suppl/GSM1174408_ETB65_++.CEL.gz","28434","Mesenchymal Cell","female","Proliferative Stage","endometrium"
"GSM1174409","Control Endometrium Endothelial Cell_ETB65 +-","GSM1174409","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Endothelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174409/suppl/GSM1174409_ETB65_+-.CEL.gz","28434","Endothelial Cell","female","Proliferative Stage","endometrium"
"GSM1174410","Control Endometrium Stromal Cell_ETB65 -+","GSM1174410","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Stromal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174410/suppl/GSM1174410_ETB65_-+.CEL.gz","28434","Stromal Cell","female","Proliferative Stage","endometrium"
"GSM1174411","Control Endometrium Stromal Cell_013.UC182-+","GSM1174411","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Stromal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174411/suppl/GSM1174411_013.UC182-+.CEL.gz","28434","Stromal Cell","female","Proliferative Stage","endometrium"
"GSM1174412","Control Endometrium Epithelial Cell_014.UC182_EpCAM","GSM1174412","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Epithelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174412/suppl/GSM1174412_014.UC182_EpCAM.CEL.gz","28434","Epithelial Cell","female","Proliferative Stage","endometrium"
"GSM1174413","Control Endometrium Mesenchymal Cell_015.UC182++new","GSM1174413","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Mesenchymal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174413/suppl/GSM1174413_015.UC182++new.CEL.gz","28434","Mesenchymal Cell","female","Proliferative Stage","endometrium"
"GSM1174414","Control Endometrium Endothelial Cell_016.UC182+-new","GSM1174414","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Endothelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174414/suppl/GSM1174414_016.UC182+-new.CEL.gz","28434","Endothelial Cell","female","Proliferative Stage","endometrium"
"GSM1174415","Control Endometrium Stromal Cell_029.UC208-+","GSM1174415","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Stromal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174415/suppl/GSM1174415_029.UC208-+.CEL.gz","28434","Stromal Cell","female","Proliferative Stage","endometrium"
"GSM1174416","Control Endometrium Epithelial Cell_030.UC208_EpCAM","GSM1174416","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Epithelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174416/suppl/GSM1174416_030.UC208_EpCAM.CEL.gz","28434","Epithelial Cell","female","Proliferative Stage","endometrium"
"GSM1174417","Control Endometrium Mesenchymal Cell_031.UC208++","GSM1174417","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Mesenchymal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174417/suppl/GSM1174417_031.UC208++.CEL.gz","28434","Mesenchymal Cell","female","Proliferative Stage","endometrium"
"GSM1174418","Control Endometrium Endothelial Cell_032.UC208+-","GSM1174418","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Endothelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174418/suppl/GSM1174418_032.UC208+-.CEL.gz","28434","Endothelial Cell","female","Proliferative Stage","endometrium"
"GSM1174419","Control Endometrium Epithelial Cell_034.UC209_EpCAM","GSM1174419","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Epithelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174419/suppl/GSM1174419_034.UC209_EpCAM.CEL.gz","28434","Epithelial Cell","female","Proliferative Stage","endometrium"
"GSM1174420","Control Endometrium Mesenchymal Cell_035.UC209++)","GSM1174420","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Mesenchymal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174420/suppl/GSM1174420_035.UC209++.CEL.gz","28434","Mesenchymal Cell","female","Proliferative Stage","endometrium"
"GSM1174421","Control Endometrium Endothelial Cell_036.UC209+-","GSM1174421","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Endothelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174421/suppl/GSM1174421_036.UC209+-.CEL.gz","28434","Endothelial Cell","female","Proliferative Stage","endometrium"
"GSM1174422","Control Endometrium Stromal Cell_033.UC-209-+","GSM1174422","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","Proliferative Stage Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: Proliferative Stage","cell type: Stromal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174422/suppl/GSM1174422_033.UC-209-+.CEL.gz","28434","Stromal Cell","female","Proliferative Stage","endometrium"
"GSM1174423","PCOS Endometrium Stromal Cell_101.PC01-+","GSM1174423","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Stromal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174423/suppl/GSM1174423_101.PC01-+.CEL.gz","28434","Stromal Cell","female","PCOS","endometrium"
"GSM1174424","PCOS Endometrium Mesenchymal Cell_102.PC01++","GSM1174424","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Mesenchymal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174424/suppl/GSM1174424_102.PC01++.CEL.gz","28434","Mesenchymal Cell","female","PCOS","endometrium"
"GSM1174425","PCOS Endometrium Endothelial Cell_103.PC01+-","GSM1174425","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Endothelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174425/suppl/GSM1174425_103.PC01+-.CEL.gz","28434","Endothelial Cell","female","PCOS","endometrium"
"GSM1174426","PCOS Endometrium Stromal Cell_104.PC07-+","GSM1174426","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Stromal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174426/suppl/GSM1174426_104.PC07-+.CEL.gz","28434","Stromal Cell","female","PCOS","endometrium"
"GSM1174427","PCOS Endometrium Epithelial Cell_105.PC07_EpCAM","GSM1174427","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Epithelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174427/suppl/GSM1174427_105.PC07_EpCAM.CEL.gz","28434","Epithelial Cell","female","PCOS","endometrium"
"GSM1174428","PCOS Endometrium Mesenchymal Cell_106.PC07++","GSM1174428","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Mesenchymal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174428/suppl/GSM1174428_106.PC07++.CEL.gz","28434","Mesenchymal Cell","female","PCOS","endometrium"
"GSM1174429","PCOS Endometrium Endothelial Cell_107.PC07+-","GSM1174429","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Endothelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174429/suppl/GSM1174429_107.PC07+-.CEL.gz","28434","Endothelial Cell","female","PCOS","endometrium"
"GSM1174430","PCOS Endometrium Epithelial Cell_109.PC08_EpCAM","GSM1174430","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Epithelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174430/suppl/GSM1174430_109.PC08_EpCAM.CEL.gz","28434","Epithelial Cell","female","PCOS","endometrium"
"GSM1174431","PCOS Endometrium Stromal Cell_118.PC11-+","GSM1174431","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Stromal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174431/suppl/GSM1174431_118.PC11-+.CEL.gz","28434","Stromal Cell","female","PCOS","endometrium"
"GSM1174432","PCOS Endometrium Epithelial Cell_119.PC11_EpCAM","GSM1174432","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Epithelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174432/suppl/GSM1174432_119.PC11_EpCAM.CEL.gz","28434","Epithelial Cell","female","PCOS","endometrium"
"GSM1174433","PCOS Endometrium Mesenchymal Cell_120.PC11++","GSM1174433","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Mesenchymal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174433/suppl/GSM1174433_120.PC11++.CEL.gz","28434","Mesenchymal Cell","female","PCOS","endometrium"
"GSM1174434","PCOS Endometrium Stromal Cell_134.UC271-+","GSM1174434","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Stromal Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174434/suppl/GSM1174434_134.UC271-+.CEL.gz","28434","Stromal Cell","female","PCOS","endometrium"
"GSM1174435","PCOS Endometrium Epithelial Cell_138.UC271 EpCAM","GSM1174435","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Epithelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174435/suppl/GSM1174435_138.UC271_EpCAM.CEL.gz","28434","Epithelial Cell","female","PCOS","endometrium"
"GSM1174436","PCOS Endometrium Endothelial Cell_140.UC271+-","GSM1174436","Public on Sep 30 2013","Jun 26 2013","Sep 30 2013","RNA","1","PCOS Endometrial Biopsy","Homo sapiens","gender: female","tissue: endometrium","phase: PCOS","cell type: Endothelial Cell","Tissue Processing and Fluorescence Activated Cell Sorting (FACS) of Endometrial Cell Populations:","Tissue biopsies were divided into two fresh tissue samples processed separately for fluorescence activated cell sorting (FACS) and for histological examination in formalin-fixed, paraffin embedded tissue. Tissue processing for viable cell isolation and FACS analysis were performed as previously described (15). Briefly, enzymatically dissociated endometrial cells were incubated in blocking buffer (PBS with 40% human serum [HS] and 1% bovine serum albumin [BSA]) for 30min then labeled with the following fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) in PBS containing 10% HS and 1% BSA: cluster of differentiation 45 (CD45, PE-Cy7 anti-CD45) at 1:20 dilution to label contaminating leukocytes for their removal; epithelial cell adhesion molecule (EPCAM, allophycocyanin anti-EPCAM) at 1:20 dilution to label eEP; cluster of differentiation 146 (CD146 or melanoma cell adhesion molecule [MCAM], CD146, fluorescein isothiocyanate anti-MCAM) at 1:5 dilution to label eEN/perivascular cells; beta-type platelet-derived growth factor receptor (PDGFRB, phycoerythrin (PE) anti-PDGFRB) at 1:5 dilution to label eSF. eMSCs were sorted using double labeling for CD146 and PDGFRB antibodies respectively, both at 1:5 dilutions. The cell suspension was sorted using a FACS Aria II with FACS Diva software (BD Biosciences). The FACS-sorted cell pellets were stored at -80C until RNA extraction.","FACS analyzed sorted cell populations were subject to RNA isolation and purification, with DNAse treatment, using Pico Pure RNA Isolation Kit","total RNA","Total RNA was isolated form FACS-sorted cell populations and purified using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA) following manufacturer´s instructions. An additional DNase treatment was performed using the RNase-Free DNase Set (Qiagen, Valencia, CA).","Biotin","Reverse transcription and amplification of isolated RNA into cDNA was performed using NuGEN WT-Ovation Exon FFPE System V2 (NuGen, San Carlos, CA). The integrity of resultant cDNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies), and individual samples meeting yield and quality standards were further processed and hybridized to Affymetrix Human Gene 1.0 ST arrays (Affymetrix, Cleveland, OH), probing 36,079 genes.","9606","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in the WT sense target labeling assay manual from Affymetrix (version 4; FS450_0007).","Microarrays were hybridized, washed, stained, and scanned according to the protocol described in WT Sense Target Labeling Assay Manual from Affymetrix (Version 4; FS450_0007) at the UCSF Gladstone Genomics Core Facility.","GeneSpringGX 11, Microarray Technology: Affymetrix.ExonExprChip.HuGene-1_0-st-v1, Summarization Algorithm: ExonRMA16, Normalization: Quantile, Baseline Transformation: median of all samples","Summarization Algorithm: RMA16. Transcript Level: Core. Baseline to median of all samples","GPL6244","Linda,,Giudice","giudice@obgyn.ucsf.edu","415-476-2039","Giudice Lab","OBGYN and RS","University of California, San Francisco","513 Parnassus Ave. HSE 1619","San Francisco","CA","94122","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1174nnn/GSM1174436/suppl/GSM1174436_140.UC271+-.CEL.gz","28434","Endothelial Cell","female","PCOS","endometrium"
